ScholarLens Back to search
2013•MD Conference ExpressRequires access

Long-Term Ranibizumab Effective in Diabetic Macular Edema

Emmalee Nichols, Anna Boixadera

Open publisher page 0 citations

Abstract

In patients with diabetic macular edema, long-term intravitreal injections of ranibizumab maintains best-corrected visual acuity and central retinal subfield thickness improvements over 36 months, with no new or increased safety concerns. This article discusses the final analysis of the 36-month study comprising: A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-Label Extension Study [RESTORE; NCT00687804].

About this research paper

What this paper is about

In patients with diabetic macular edema, long-term intravitreal injections of ranibizumab maintains best-corrected visual acuity and central retinal subfield thickness improvements over 36 months, with no new or increased safety concerns. This article discusses the final analysis of the 36-month study comprising: A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-Label Extension Study [RESTORE; NCT00687804].

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In patients with diabetic macular edema, long-term intravitreal injections of ranibizumab maintains best-corrected visual acuity and central retinal subfield thickness improvements over 36 months, with no new or increased safety concerns. This article discusses the final analysis of the 36-month study comprising: A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-Label Extension Study [RESTORE; NCT00687804].

Key concepts: Medicine, Ranibizumab, Diabetic macular edema, Ophthalmology, Macular edema, Visual acuity, Retinal, Edema

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Long-Term Ranibizumab Effective in Diabetic Macular Edema — Research Paper | ScholarLens